Vanda says EU grants orphan drug status to imsidolimab for generalized pustular psoriasis
VNDA•EU orphan designation and FDA review
Vanda said the European Commission granted orphan designation for imsidolimab to treat generalized pustular psoriasis, a rare, potentially life-threatening inflammatory skin disease.
The FDA is reviewing the imsidolimab BLA for generalized pustular psoriasis, with an action date of Dec. 12, 2026.
